GlassScriptPhysician profile
Joseph Moran
NPI 1942734173
$4,426.39
in general payments reported to CMS, 2019-2025
33 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $499 · 2022: $887 · 2023: $297 · 2024: $356 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $726.97 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $398.81 | 2022-2025 | Fasenra, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.00 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.74 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Jascayd |
| Janssen Pharmaceuticals, INC | $293.80 | 2019-2020 | |
| Genzyme Corporation | $248.78 | 2022-2025 | |
| Abbvie INC. | $190.94 | 2020-2025 | |
| Medtronic, INC. | $171.06 | 2022 | |
| Mylan Specialty L.P. | $141.88 | 2022-2024 | Yupelri |
| Novo Nordisk INC | $139.68 | 2022-2025 | Wegovy |
| Insmed, INC. | $125.42 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $124.80 | 2020 | |
| Valeritas, INC. | $114.31 | 2019 | |
| Pfizer INC. | $107.27 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $100.63 | 2022-2025 | Dupixent |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $97.31 | 2022-2025 | Aralast |
| Verona Pharma, INC. | $94.01 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $88.86 | 2022-2023 | Acthar |
| Genentech USA, INC. | $87.92 | 2022-2025 | Xolair |
| Merck Sharp & Dohme LLC | $72.60 | 2019-2025 | Winrevair |
| United Therapeutics Corporation | $65.69 | 2022-2025 | Tyvaso, Tyvaso |
| Baxter Healthcare | $62.52 | 2025 | |
| Philips North America LLC | $60.69 | 2022-2025 | Vest Therapy Und |
| Amgen INC. | $54.20 | 2022-2025 | Tezspire |
| Harmony Biosciences LLC | $53.69 | 2025 | |
| Becton, Dickinson and Company | $47.78 | 2025 | Hemosphere |
| Actelion Pharmaceuticals US, INC. | $29.46 | 2022 | |
| Boston Scientific Corporation | $18.78 | 2023 | |
| Azurity Pharmaceuticals, INC. | $18.13 | 2025 | Horizant |
| Electromed, INC. | $17.49 | 2025 | Smartvest |
| Viatris Specialty LLC | $16.99 | 2025 | Yupelri |
| Lilly USA, LLC | $15.84 | 2025 | Mounjaro, Zepbound |
| Ani Pharmaceuticals, INC. | $15.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.